StockWireNews
Keep Eyes On This Low Float NASDAQ Profile With Recent Major News - Displays Wild Upside Potential
DJS $7.00 Price Target / Analyst Report
April 3rd
Good Morning,
Have you read this week's news from Citius Pharmaceuticals, Inc. (CTXR)?
With the global pandemic not looking like it will come to an end anytime soon, it will be important to watch companies trying to provide/create services that could help combat this virus.
That's why after yesterday's pullback, CTXR could be potentially undervalued with tons of upside potential.
Additionally, it could see some serious support from its 13-Day Exponential Moving Average (approximately $.61 after hours Thursday).
Read the news below now:
Citius Signs Exclusive Option with Novellus to License Novel Stem-Cell Therapy for Acute Respiratory Distress Syndrome (ARDS) Associated with CV-19
- Novellus's patented mRNA-based cell-reprogramming technology creates unique mesenchymal stem cells (MSCs) with superior immunomodulatory properties and manufacturing advantages over primary adult donor-derived MSCs - much greater supply and faster scale-up
- MSCs prevent and suppress cytokine storm believed to be the cause of the severe inflammation of ARDS and now seen in CV-19 patients
CRANFORD, N.J., April 1, 2020 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today signed an exclusive six-month option agreement to in-license a stem-cell therapy for acute respiratory distress syndrome (ARDS) from a subsidiary of Novellus, Inc., a preclinical-stage biotechnology company based in Cambridge, MA.
Novellus's patented process uses its exclusive non-immunogenic synthetic messenger ribonucleic acid (mRNA) molecules to create induced pluripotent stem cells (iPSCs) that, in turn, generate mesenchymal stem cells (MSCs) with superior immunomodulatory properties. MSCs have been shown to be safe in over 900 clinical trials and to be safe and effective in treating a number of inflammatory diseases, including ARDS.
Read The Full Article Here.
-----
A $7.00 Price Target Gives CTXR Serious Potential Upside
A rough calculation from CTXR's Thursday's close (approximately $.7399 per share), gives this stock profile a ton of upside potential.
If CTXR is able to find enough momentum to push through its 52-week high of $1.50 in the short-term, this stock could really start making moves.
Link Dawson James Securities Analyst Report.
-----
